Actio Biosciences Begins Trial for KCNT1 Epilepsy Treatment
September 23, 2025
Actio Biosciences, a clinical-stage biotechnology company leveraging a novel approach to genetics and precision medicine to develop new small molecule therapeutics that target shared underlying